Clinical Trial Update: Evaluation of Repeat Administration of Purified Poloxamer 188 [Phase 3]

View source ↗

Summary

The document provides an update on a Phase 3 trial evaluating repeat administration of MST-188 (purified poloxamer 188) for sickle cell disease, noting the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• MST-188 (Purified poloxamer 188) (poloxamer 188)

Snippet

Sponsor: Mast Therapeutics, Inc. | Conditions: Sickle Cell Disease | Phase 3 | Status: COMPLETED